Abstract
Aims: A series of 1,4-dihydropyridine based compounds bearing benzylpyridinium moiety have been designed and evaluated for in vitro anticancer activity against glioblastoma U87MG, lung cancer A549 and colorectal adenocarcinoma Caco-2 cell lines using the MTT assay.
Method: Among these compounds, 7b, 7d, 7e, and 7f exhibited potent anticancer activity against the cell lines tested. The cytotoxicity of the synthesized derivatives was compared to standard drugs (carboplatin, gemcitabine, and daunorubicin). Result: Thus, synthesized 1,4-dihydropyridines can be considered as the encouraging molecules for further drug development as anticancer agents.Keywords: Anticancer activity, antipoliferative activity, benzylpyridinium salt, 1, 4-dihydropyridine, MTT assay.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent
Volume: 17 Issue: 7
Author(s): Denish Viradiya, Sheefa Mirza, Faraz Shaikh, Rajesh Kakadiya*, Anand Rathod, Nayan Jain, Rakesh Rawal*Anamik Shah*
Affiliation:
- Center of Excellence, National Facility for Drug Discovery Center, Department of Chemistry, Saurashtra University, Rajkot,India
- Gujarat Cancer Research Institute, Asarwa, Ahmedabad, Gujarat,India
- Center of Excellence, National Facility for Drug Discovery Center, Department of Chemistry, Saurashtra University, Rajkot,India
Keywords: Anticancer activity, antipoliferative activity, benzylpyridinium salt, 1, 4-dihydropyridine, MTT assay.
Abstract: Aims: A series of 1,4-dihydropyridine based compounds bearing benzylpyridinium moiety have been designed and evaluated for in vitro anticancer activity against glioblastoma U87MG, lung cancer A549 and colorectal adenocarcinoma Caco-2 cell lines using the MTT assay.
Method: Among these compounds, 7b, 7d, 7e, and 7f exhibited potent anticancer activity against the cell lines tested. The cytotoxicity of the synthesized derivatives was compared to standard drugs (carboplatin, gemcitabine, and daunorubicin). Result: Thus, synthesized 1,4-dihydropyridines can be considered as the encouraging molecules for further drug development as anticancer agents.Export Options
About this article
Cite this article as:
Viradiya Denish, Mirza Sheefa, Shaikh Faraz, Kakadiya Rajesh*, Rathod Anand, Jain Nayan, Rawal Rakesh*, Shah Anamik*, Design and Synthesis of 1,4-dihydropyridine Derivatives as Anti-cancer Agent, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666161206143251
DOI https://dx.doi.org/10.2174/1871520616666161206143251 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Na+-H+ Exchanger, pH Regulation and Cancer
Recent Patents on Anti-Cancer Drug Discovery A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets Designing Novel Therapies Against Sarcomas in the Era of Personalized Medicine and Economic Crisis
Current Pharmaceutical Design Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets The Purinome, a Complex Mix of Drug and Toxicity Targets
Current Topics in Medicinal Chemistry Withdrawal Notice: STK33-Dependent Transcriptional Regulation of SFTA3 Induces Cisplatin-Resistance in Lung Adenocarcinoma
Anti-Cancer Agents in Medicinal Chemistry P-glycoprotein Inhibition: The Past, the Present and the Future
Current Drug Metabolism Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Nanotechnology, A Tool for Diagnostics and Treatment of Cancer
Current Topics in Medicinal Chemistry Identification of a Linear Epitope Recognized by a Monoclonal Antibody Directed to the Heterogeneous Nucleoriboprotein A2
Protein & Peptide Letters Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma
Current Pharmaceutical Design The Role of Tumor Associated Macrophages in the Tumor Microenvironment: Mechanism and Functions
Anti-Cancer Agents in Medicinal Chemistry Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry The Crosstalk Between the Matrix Metalloprotease System and the Chemokine Network in Acute Myeloid Leukemia
Current Medicinal Chemistry Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Novel Action and Mechanism of Auranofin in Inhibition of Vascular Endothelial Growth Factor Receptor-3-Dependent Lymphangiogenesis
Anti-Cancer Agents in Medicinal Chemistry CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design